New chemo cocktail aims to treat rare lymphoma without heart damage
NCT ID NCT07535762
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new chemotherapy combination called CAOP for elderly patients (65+) with untreated peripheral T-cell lymphoma, a rare blood cancer. The standard treatment often causes heart damage, but this regimen replaces the heart-toxic drug with a safer one. The study will enroll 36 participants to see if the combo can achieve complete remission with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aclarubicin, cyclophosphamide, vincristine, and prednisone (CAOP regimen)
What this could lead to
If successful, this could offer a safer and effective chemotherapy option for elderly patients with peripheral T-cell lymphoma, potentially improving survival without severe heart damage.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to all patients. The drug combination may still cause side effects or fail to improve outcomes compared to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital Wuxi Branch
Wuxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••